Lurasidone for the treatment of acutely psychotic patients with schizophrenia: a 6-week, randomized, placebo-controlled study

Journal of Psychiatric Research
Henry A NasrallahAntony Loebel

Abstract

Despite the availability of established antipsychotic agents for the treatment of schizophrenia, continued unmet needs exist for effective medications with lower adverse-effect burden. The present study evaluated the efficacy, safety, and tolerability of treatment with the atypical antipsychotic lurasidone for patients with an acute exacerbation of schizophrenia. Patients were randomized to 6 weeks of double-blind treatment with lurasidone 40 mg/day, 80 mg/day, or 120 mg/day, or placebo. Changes in Positive and Negative Syndrome Scale (PANSS) scores were evaluated using mixed-model repeated-measures (MMRM) analysis. Vital signs, laboratory parameters, extrapyramidal symptoms, and electrocardiogram were assessed. Treatment with lurasidone 80 mg/day resulted in significantly greater improvement in PANSS total score compared with placebo (-23.4 versus -17.0; p < 0.05) at study endpoint (MMRM); lurasidone 40 mg/day and 120 mg/day achieved clinically meaningful overall PANSS score reductions from baseline (-19.2 and -20.5), but not significant separation from placebo. Differences between all lurasidone groups and placebo for changes in laboratory parameters and electrocardiographic measures were minimal. Weight gain ≥ 7% occurred in...Continue Reading

References

Jan 31, 2015·Expert Opinion on Investigational Drugs·Mauro Giovanni CartaJoseph R Calabrese
Nov 18, 2014·Expert Opinion on Drug Safety·Richard MusilMichael Hamerle
Jul 1, 2014·Expert Opinion on Drug Safety·Felix-Martin Werner, Rafael Coveñas
Jan 16, 2016·Annals of the New York Academy of Sciences·Antony LoebelAndrei Pikalov
Dec 15, 2015·Journal of Autism and Developmental Disorders·Antony LoebelRobert L Findling
Jun 27, 2015·Expert Opinion on Pharmacotherapy·Dawn BruijnzeelRajiv Tandon
Apr 14, 2016·PharmacoEconomics·Krithika RajagopalanAntony Loebel
Apr 17, 2014·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·D Bugarski-KirolaT Blättler
Oct 5, 2014·European Psychiatry : the Journal of the Association of European Psychiatrists·Antony LoebelS R Marder
Feb 5, 2014·Schizophrenia Bulletin·Stefan LeuchtJohn M Davis
Dec 10, 2016·Evidence-based Mental Health·Simon Wandel, Satrajit Roychoudhury
Jul 8, 2017·Expert Opinion on Investigational Drugs·Lynn McClellanCraig A Erickson
Nov 21, 2017·Statistics in Medicine·Alex Dmitrienko, Ralph B D'Agostino
Feb 3, 2016·Therapeutic Advances in Psychopharmacology·Steven G PotkinJohn Guarino
May 31, 2018·The New England Journal of Medicine·Alex Dmitrienko, Ralph B D'Agostino
Apr 27, 2018·Journal of Comparative Effectiveness Research·Daisy Ng-MakAntony Loebel
Sep 14, 2017·Expert Opinion on Drug Safety·Maurizio PompiliPaolo Girardi
Dec 15, 2019·Asia-Pacific Psychiatry : Official Journal of the Pacific Rim College of Psychiatrists·Teruhiko HiguchiKatsuhiko Hagi
Dec 17, 2019·The American Journal of Psychiatry·Stefan LeuchtJohn M Davis
Jan 31, 2020·Indian Journal of Dermatology, Venereology and Leprology·Sayanta Thakur, Sandeep Lahiry
Apr 26, 2020·Journal of Clinical Psychopharmacology·Herbert Y MeltzerMyung A Lee
Apr 29, 2020·Pharmacotherapy·Constance L ChowAmy M VandenBerg
Jul 22, 2015·International Clinical Psychopharmacology·Jonathan M MeyerAntony Loebel
Jul 31, 2020·Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova·S K ZyryanovE S Mosolova
Apr 5, 2016·Expert Review of Neurotherapeutics·Robert E Davis, Christoph U Correll
May 6, 2017·Journal of Child and Adolescent Psychopharmacology·Robert GoldmanRobert L Findling
Nov 28, 2017·Journal of Biopharmaceutical Statistics·Gautier Paux, Alex Dmitrienko
Apr 6, 2019·Asia-Pacific Psychiatry : Official Journal of the Pacific Rim College of Psychiatrists·Teruhiko HiguchiTakayuki Sato
Jan 23, 2018·Journal of Biopharmaceutical Statistics·Alex Dmitrienko

Citations

Apr 1, 1979·The British Journal of Psychiatry : the Journal of Mental Science·S A Montgomery, M Asberg
May 1, 1989·The British Journal of Psychiatry : the Journal of Mental Science·T R Barnes
Jan 1, 1987·Schizophrenia Bulletin·S R KayL A Opler
Jan 1, 1970·Acta Psychiatrica Scandinavica. Supplementum·G M Simpson, J W Angus
May 27, 2005·PLoS Medicine·Sukanta SahaJohn McGrath
Sep 21, 2005·The New England Journal of Medicine·Jeffrey A LiebermanClinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators
Jun 6, 2009·The Journal of Clinical Psychiatry·Mitsutaka NakamuraAntony Loebel
Apr 21, 2010·The Journal of Pharmacology and Experimental Therapeutics·Tadashi IshibashiMitsutaka Nakamura
Apr 26, 2011·Journal of Biopharmaceutical Statistics·Thomas BrechenmacherAjit C Tamhane
Jun 17, 2011·The American Journal of Psychiatry·Herbert Y MeltzerAntony Loebel
Aug 21, 2012·Psychopharmacology·Masaaki OgasaJohn Guarino

Related Concepts

Glycated Hemoglobin TEST
Metabolic Process, Cellular
PRL
Antipsychotic Effect
Atypical Antipsychotic [EPC]
Glucose Metabolism Disorders
Schizophrenia
Serotonin
Fetishism (Psychiatric)
Extrapyramidal Sign

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.

Antipsychotic-Induced Weight Gain

Antipsychotic-induced weight gain (aiwg) is a common adverse effect of this treatment, particularly with second-generation antipsychotics, and it is a major health problem around the world. Here are the latest discoveries pertaining to AIWG.